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A B S T R A C T
Background: The prevalence of severe sclerotic aortic stenosis (ScAS) in those at least 380 years old has
been increasing in Japan; however, the prognosis of these Japanese patients without surgical treatment
has not been reported.
Methods and results: Ninety consecutive patients with medically treated severe ScAS were prospectively
studied. To assess further event-free survival rate (EFSR) from either cardiac (heart failure or cardiac
death) events or noncardiac deaths, they were divided into three groups based on aortic valve area (AVA)
at the initial diagnosis (group A: AVA 2 0.6 cm2, group B: 0.6 cm2 < AVA 2 0.8 cm2, and group C:
0.8 cm2 < AVA 2 1.0 cm2). In comparison, 73 consecutive patients 380 years old with moderate ScAS
(group M: 1.0 cm2 < AVA 2 1.5 cm2) were also enrolled. The EFSR in group A was signiﬁcantly lower
than that in the other groups (p < 0.05) while no difference was seen among the other groups although
the EFSR from cardiac events in group B was lower than the moderate group (p < 0.05). Multivariate
analysis showed that the cardiac risk factors were AVA 20.6 cm2 and left ventricular ejection fraction
(EF) 255%.
Conclusions: Since patients with AVA 20.6 cm2 have a signiﬁcantly worse prognosis, more symptoms,
and higher prevalence of cardiac events, early aortic valve replacement should be considered in this
group. Furthermore, patients having AVA ranging from 0.6 to 0.8 cm2 have a worse prognosis in cardiac
events compared to group M. In addition, EF 255% is another signiﬁcant factor for cardiac events.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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An acute increase in the Japanese population at least 380 years
old has resulted in a dramatic increase in patients with sclerotic aortic
stenosis (ScAS). The mean age at the initial diagnosis of severe ScAS in
the authors’ previous study was 79 years in males and 82 years in
females [1]. Varadarajan et al. [2] report,however, that only 20% of the
elderly patients 380 years old with severe AS have undergone aortic
valve replacement (AVR) because of their comorbidities or age.
Although several reports have demonstrated the safety of AVR even
in elderly patients [3,4], the rate of AVR in patients 380 years
old remains low [2,5]. According to the 2008 American College
of Cardiology/American Heart Association (ACC/AHA) practice* Corresponding author at: Division of Cardiology, Cardiovascular Center,
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsguidelines for AS [6], the surgical indications for severe aortic
stenosis (AS) [aortic valve area (AVA) <1.0 cm2 or indexed AVA
(AVAI) <0.6 cm2] include symptomatic AS or left ventricular ejection
fraction (EF) 250%. Debate still occurs in Japan, however, about
whether AVA 21.0 cm2 is an optimal indicator for AVR [7]. Since no
report investigating the prognosis of Japanese patients with ScAS
without AVR has yet been published, the appropriate severity of AS
for AVR remains controversial [7]. To assess the prognosis of Japanese
patients 380 years old with ScAS and without AVR; therefore, this
prospective long-term follow-up study has been conducted.
Methods
Initially, 131 consecutive patients 380 years old with severe
ScAS, AVA 21.0 cm2, refusing AVR, or having contraindications for
AVR at the initial diagnosis were enrolled in this study from
November 17, 2003 to December 31, 2010. Exclusion criteria
included those with bicuspid aortic valves, rheumatic AS, or regular
hemodialysis treatments. In addition, 20 patients with critical reserved.
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deﬁcits, severe cirrhosis, and end-stage cancer with a predicted
survival period less than 6 months, at the initial diagnosis were
excluded.
One hundred and eleven patients, thus, were enrolled in
this study. To compare the prognosis of severe ScAS, 74
consecutive patients 380 years old with moderate ScAS
(1.0 cm2 < AVA 2 1.5 cm2) were also enrolled (group M); they
were initially diagnosed in our hospital from January 1, 2004 to
July 31, 2010. Enrollment criteria for group M were the same as
described above for the severe ScAS group. Written informed
consent was obtained in advance from all the patients for regular
follow-up at the outpatient clinic. Patients who were unable to
attend follow-up in the outpatient clinic were interviewed by
telephone once or twice a year about their condition.
Blood pressure measurement, physical examination, echocar-
diogram, logistic EuroScore, and laboratory data were performed at
the initial diagnosis. Since accurate evaluation of New York Heart
Association classiﬁcation of elderly patients is sometimes difﬁcult
due to restriction of activities, such as arthritis, lower back pain, or
neurological deﬁcits, the activities of daily living (ADL) were
evaluated also during the initial diagnosis. The degree of ADL was
classiﬁed as follows: no personal assistance needed = 0, partial
personal assistance needed = 1, and total personal assistance
needed = 2.
The AVA was measured by using a continuous equation, and the
transaortic pressure gradient (AVPG) was calculated as 4  (trans-
(transaortic peak ﬂow velocity)2. Left ventricular volume was
measured by the modiﬁed Simpson method by using two-
dimensional echocardiography, and the left ventricular mass
index was calculated by the reported equation [8]. Systemic
vascular resistance was calculated as (80  mean arterial pres-
sure)/cardiac output. E0 was used in the lateral mitral annulus
velocity measured by the pulsed Doppler method. Both the
transmitral velocities in the left ventricular rapid ﬁlling phase (E)
and atrial kick (A) were also measured by pulsed Doppler method.
The E/E0 and E/A were calculated as indices of the left ventricular
diastolic function.
For further assessment of the prognosis of ScAS based on
the AVA, patients with severe ScAS were divided into three
groups by the initial AVA (group A: AVA 20.6 cm2, group B:
0.6 cm2 < AVA 2 0.8 cm2, and group C: 0.8 cm2 < AVA 2 1.0 cm2).
Primary endpoints were cardiac [heart failure (HF) or cardiac
death] or noncardiac (noncardiac death) events. If patients had
HF before they died by a cardiac or noncardiac cause, the cardiac
event was considered as HF. When patients died, the dates andTable 1
Clinical characteristics of patients’ having AVR after the study began.
1 2 
Age (years) 84 87 
Sex F F 
Symptoms Chest pain
dyspnea on
exertion
Dyspnea 
AVA (cm2) 0.4 0.4 
Ejection fraction (%) 72 66 
Logistic EuroScore (%) 6.1 7.4 
Degree of personal assistance
of activities of daily living
0 0 
Initial reason for avoiding AVR Refused Refused 
Reason of AVR after enrollment
in this study
Changed mind Changed mi
AVR, aortic valve replacement; AVA, aortic valve area.causes of death were found through the medical charts or family
interviews.
In this study, HF was diagnosed according to the criteria of the
Framingham study [9]. Liver dysfunction and chronic kidney
disease were deﬁned by those values exceeding the normal range
in the study’s laboratory.
The indications for AVR were in accordance with the 2008 ACC/
AHA practice guidelines for AS [6]. Absolute indications of AVR
included severe AS (AVA <1.0 cm2) with symptoms and/or EF
250%. Undergoing coronary artery bypass graft surgery and/or
surgery on the aorta or other heart valves were other indications
for concomitant AVR. In patients 380 years old, however, many
patients had no symptoms even if AS was severe. In such
asymptomatic, severe ScAS, elderly patients, they were recom-
mended to undergo AVR unless otherwise contraindicated.
Statistical analysis
Differences in age, body surface area (BSA), follow-up periods,
echocardiographic parameters, logistic EuroScores, degrees of ADL,
and laboratory data among the groups were analyzed by one-way
ANOVA and Newman–Keuls test. Differences in symptoms, male/
female ratios, rates of cardiac death, survival rates, comorbidities,
and medications were analyzed by Fisher’s exact test. Factors for
cardiac death in severe ScAS were analyzed by univariate and
multivariate analyses. The critical cut-off point of each parametric
variable for univariate and multivariate analyses was determined
by receiver operating characteristic curve. Both the event-free
survival rates from cardiac and noncardiac events and from only
cardiac events among all the severe groups and group M were
analyzed by Kaplan–Meier analysis, and a signiﬁcant difference of
event-free survival rates from those endpoints was analyzed by
log-rank test. Signiﬁcant difference was accepted if p < 0.05.
Results
In the severe ScAS group, because 16 patients dropped out and 5
underwent AVR, only 90 patients could be followed up (group A: 24
patients, group B: 32 patients, and group C: 34 patients) to assess
their prognosis without AVR. In group M, 73 patients were
followed up because 1 patient underwent AVR. Table 1 lists the
patients who underwent AVR after the study was begun. Four
patients initially refused AVR despite the possibility of AVR but
were all eventually successfully convinced otherwise. Only one
patient had a contraindication at the enrollment of this study
because of uncontrolled hyperthyroidism, but when controlled,Patient
3 4 5
80 80 81
F F F
Chest pain
dyspnea
None Dyspnea on
exertion
0.7 0.9 0.9
76 64 59
4.8 4.8 5.1
0 0 0
Uncontrolled
hyperthyroidism
Refused Refused
nd Controlled
hyperthyroidism
Changed
mind
Changed
mind
Table 2
Clinical background at the initial diagnosis in groups with severe and moderate sclerotic aortic stenosis.
Group
A B C M
n 24 32 34 73
Age (years) 88  6 89  6 87  4 85  3
Male/female 5/19 10/22 8/26 21/52
Follow-up periods (years) 2.2  2.0 2.3  2.0 2.3  1.7 2.9  1.6
Body surface area (m2) 1.47  0.15 1.48  0.19 1.40  0.11 1.47  0.13
Symptoms (%) 63 19** 32+ 18**
Chest pain 4 3 2 7
Dyspnea 10 3 7 11
Syncope 2 1 2 0
Smoking (%) 11 30 23 31
Mean arterial pressure (mmHg) 113  24 112  28 117  19 122  19
Logistic EuroScore (%) 20.5  14.0 18.3  14.3 13.5  6.9 11.1  6.4*,#
Degree of activities of daily living 0.7  0.9 0.7  0.9 0.5  0.8 0.6  0.7
Medications
Angiotensin-receptor blocker (%) 4 16 35 26
Angiotensin-converting enzyme
inhibitor (%)
38 16 15 25
Calcium antagonist (%) 42 50 59 50
b-Blocker (%) 17 16 9 13
Diuretic (%) 29 31 38 47
Statin (%) 29 22 15 15
* vs. group A: <0.001.
** vs. group A: <0.01.
+ vs. group A: <0.05.
# vs. group B: <0.05.
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follow up and/or could not be reached. Table 2 shows the clinical
background of all groups. Age, male/female ratio, BSA, mean
arterial pressure, degree of ADL, and medications at the initial
diagnosis were not different among the groups. In all of the severe
ScAS groups, patients with partial or total assistance needed were
48.9% while those in group M were 46.6%. The number of
symptomatic patients at the initial diagnosis in group A was
signiﬁcantly greater than the other groups (p < 0.01 vs. groups BTable 3
Comorbidities and laboratory data at the initial diagnosis in groups with severe and m
A 
Comorbidities
Diabetes mellitus (%) 25 
Hypertension (%) 63 
Dyslipidemia (%) 46 
Coronary artery disease (%) 13 
Peripheral artery disease (%) 13 
Cerebrovascular accident (%) 17 
Atrial ﬁbrillation (%) 25 
Chronic kidney disease (%) 25 
Cancer (%) 17 
Liver dysfunction (%) 0 
Pulmonary disease (%) 4 
Dementia (%) 33 
Laboratory data
Total protein (g/dL) 6.7  0.6 
Creatinine (g/dL) 1.47  1.44 
Hemoglobin (g/dL) 11.3  2.0 
Total cholesterol (mg/dL) 187  48 
Triglyceride (mg/dL) 96  44 
Brain natriuretic peptide (pg/dL) 890  697 
NM: not measured.
* vs. group A: <0.01.
** vs. groups A–C: <0.05.
+ vs. group A: <0.05.and M, p < 0.05 vs. group C). Dyspnea and chest pain were the most
common symptoms while syncope was rarely experienced. On the
other hand, symptoms in groups B, C, and M were only seen in 20–
30%. Logistic EuroScore in group M was signiﬁcantly lower than in
group A (p < 0.001) and group B (p < 0.05).
Table 3 shows the comorbidities and laboratory data at the initial
diagnosis. The percentage of patients having dyslipidemia (p < 0.01)
and dementia (p < 0.05) in group M was less than those in group A.
The percentage of patients having coronary artery disease in groupoderate sclerotic aortic stenosis.
Group
B C M
23 21 30
56 74 74
19 9* 31*
13 15 33**
9 6 8
19 15 31
34 24 21
9 15 21
19 27 28
3 12 4
22 6 7
28 21 14+
6.5  0.9 6.8  0.8 6.7  1.2
0.90  0.46 1.15  0.94 1.01  0.60
11.3  1.91 1.2  2.0 11.8  2.4
178  38 185  42 191  55
84  41 85  46 105  56
504  598 372  415 NM
Table 4
Echocardiographic parameters at the initial diagnosis in groups with severe and moderate sclerotic aortic stenosis.
Group
A B C M
Heart rate (bpm) 73  17 77  15 69  11 70  14
Aortic diameter (mm) 33  3 31  3 33  4 34  4
Aortic annular diameter (mm) 19  2 19  1 20  1 20  2
Left atrial diameter (mm) 45  10 43  9 43  8 42  8
Left ventricular mass index (g/m2) 194  63 167  63 164  60 169  45
End-diastolic volume (mL) 66  20 63  18 73  33 77  25
End-systolic volume (mL) 28  20 22  12 30  25 27  18
Stroke volume (mL) 39  12 41  10 44  12 50  13*
Cardiac output (L/min) 2.8  0.6 3.1  0.9 3.0  0.9 3.4  0.9**
Ejection fraction (%) 61  19 66  10 64  11 67  12
E/A 0.7  0.5 0.7  0.2 0.7  0.4 0.6  0.2
E/E0 12  6 10  4 11  4 10  4
Estimated right ventricular systolic
pressure (mmHg)
40  11 41  13 37  11 34  9
Systemic vascular resistance
(dyn/s/cm5)
3535  1152 3173  1232 3419  1199 2963  916
Mitral annulus calciﬁcation (%) 54 50 56 40
Mitral regurgitation (0/I/II/III) 5/10/9/0 6/19/7/0 8/12/13/1 22/38/10/3
Aortic regurgitation (0/I/II/III) 6/12/6/0 8/21/3/0 17/12/5/0 35/25/12/1
AVA (cm2) 0.51  0.09 0.75  0.05 0.97  0.05 1.30  0.10
AVPG (mmHg) 89  28 55  23 45  18 33  9
AVA, aortic valve area; AVPG, aortic valve pressure gradient.
* vs. group A: <0.001.
** vs. group A: <0.05.
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difference in other laboratory data among the groups was found.
Table 4 shows the echocardiographic parameters at the initial
diagnosis. Only stroke volume (p < 0.001) and cardiac output
(p < 0.05) in group M were greater than those of group A; however,
no signiﬁcant difference in the other echocardiographic param-
eters among the groups was found.
Table 5 shows the number of patients with cardiac events,
noncardiac deaths, and survival during the follow-up period. The
rate of cardiac death during the follow-up period in group A was
signiﬁcantly greater than the other groups (p < 0.01 vs. groups B
and M, p < 0.05 vs. group C). The number of patients with HF or
noncardiac death during the follow-up period, however, was not
different among the groups. In addition, the ﬁnal survival rate of
group A was signiﬁcantly less than the other groups (p < 0.01 vs.
groups B and M, p < 0.05 vs. group C).
The event-free survival rate from cardiac or noncardiac events
of the three groups of severe ScAS and group M is demonstrated in
Fig. 1A. Group A was signiﬁcantly worse than the other groups
(p < 0.05); a difference in event-free survival rate in groups B, C,
and M was, however, not observed.Table 5
Cardiac death, heart failure, noncardiac death, and survival in groups with severe
and moderate sclerotic aortic stenosis during the follow-up period.
Group
A B C M
Cardiac death 13 (54%) 7 (22%)* 8 (24%)** 12(16%)*
Death due to
heart failure
8 5 6 8
Sudden cardiac
death
5 2 2 4
Heart failure 10 (42%) 5 (15%) 8 (24%) 8(11%)
Noncardiac death 6 (25%) 15 (47%) 26 (32%) 13(18%)
Survival 5 (21%) 10 (31%)* 15 (44%)** 48(66%)*
* vs. group A: <0.01.
** vs. group A: <0.05.The event-free survival rate from only cardiac events of the
three groups of severe ScAS and group M based on AVA is shown in
Fig. 1B. Group A was signiﬁcantly worse than the other groups
(p < 0.05), and group B was worse than group M (p < 0.05). A0 
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Fig. 1. Event-free survival rates from cardiac (cardiac death or heart failure) or
noncardiac (noncardiac death) events (A) and that from only cardiac events (cardiac
death and heart failure) (B) after the initial diagnosis of groups 380 years old in
severe (A, B, and C) and moderate (M) sclerotic aortic stenosis based on aortic valve
area.
Table 6
Factors for cardiac death and heart failure in severe sclerotic aortic stenosis.
Odds
ratio
95% conﬁdence
interval
p
Univariate analysis
AVA 20.6 cm2 4.334 1.437–13.633 0.004
Age 386 years 2.520 0.868–8.097 0.067
Female 0.633 0.210–1.954 0.436
Mitral regurgitation 32 3.807 1.343–11.180 0.0069
EF 255% 6.108 1.842–22.743 0.0009
Coronary artery disease 0.396 0.039–2.063 0.326
Diabetesmellitus 1.022 0.305–3.168 1
Hypertension 0.423 0.151–1.169 0.095
Atrial ﬁbrillation 0.798 0.243–2.407 0.801
Chronic kidney disease 0.852 0.177–3.345 1
Angiotensin-converting
enzyme inhibitor
0.732 0.184–2.499 0.782
Angiotensin receptor
blocker
0.563 0.122–2.061 0.407
Multivariate analysis
AVA 20.6 cm2 4.510 1.530–13.300 0.006
EF 255% 4.510 1.250–16.200 0.021
Mitral regurgitation 32 1.810 0.581–5.630 0.306
AVA, aortic valve area; EF, ejection fraction.
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groups C and M was not observed.
The mean BSA of all the patients was 1.47 m2. Cut-off values of
AVA such as 0.6, 0.8, and 1.0 cm2 were divided by 1.47 m2 for AVAI
values, which equaled 0.41, 0.54, and 0.68 cm2/m2, respectively,
by which all the patients were then regrouped into groups A0
(AVAI 20.41 cm2/m2), B0 (0.41 < AVAI 2 0.54 cm2/m2), C0
(0.54 < AVAI 2 0.68 cm2/m2), and M0 (0.68 < AVAI 2 1.02 cm2/m2).
The event-free survival rate from cardiac or noncardiac events
of the three groups of severe ScAS and group M0 based on AVAI is
demonstrated in Fig. 2A. Group A0 was signiﬁcantly worse than the
groups C0 and M0 (p < 0.05), but not group B0, while a difference in
event-free survival rate in groups B0 and C0 and the M0 group was,
however, not observed.
The event-free survival rate from only cardiac events in the
three groups of severe ScAS and group M0 is shown in Fig. 2B. Group
A0 was signiﬁcantly worse than groups C0 and M0 (p < 0.001), and
group B0 was signiﬁcantly worse than group M0 (p < 0.001). A
difference in the event-free survival rate from cardiac events in
groups C0 and M0 was not observed.
The factors for cardiac events, such as AVA, age, female gender,
mitral regurgitation (MR), EF, comorbidities (coronary artery
disease, chronic kidney disease, diabetes mellitus, hypertension,
and atrial ﬁbrillation), and medications (angiotensin-converting
enzyme inhibitor, angiotensin receptor blocker, and statin), were0 
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Fig. 2. Event-free survival rates from cardiac (cardiac death or heart failure) or
noncardiac (noncardiac death) events (A) and that from only cardiac events (cardiac
death and heart failure) (B) after the initial diagnosis of groups 380 years old in
severe (A0 , B0 , and C0) and moderate (M0) sclerotic aortic stenosis based on aortic
valve area index.analyzed by univariate analysis (Table 6). The cut-off points
derived from the receiver operating characteristic curve of the
above parametric variables were AVA = 0.6 cm2, age = 86 years,
and EF = 55%. An AVA 20.6 cm2, age 386 years, moderate to
severe MR, and EF 255% were recognized as signiﬁcant factors for
cardiac events by univariate analysis. Multivariate analysis,
however, showed only AVA 20.6 cm2 and EF 255% as indepen-
dent factors for cardiac events.
Discussion
Given the increase in the elderly population in Japan, the
prevalence of ScAS has also increased. In patients <80 years old
with severe ScAS, AVR should be considered if they meet the
criteria for surgery; on the other hand, patients 380 years old
infrequently undergo AVR [2,5]. In this study, only 10% of patients
380 years old with severe ScAS have undergone AVR although
many other reports have demonstrated that the risk of AVR for
these patients is not signiﬁcantly higher than other age cohorts
[2–5]. Lang et al. report [8] that comorbidities, neurogenic deﬁcits,
or lack of desire for surgery are some of the major factors for
avoiding AVR. Also, in determining the optimal timing of AVR, the
smaller BSA of Japanese patients compared to Western patients is
another important factor because it raises the question of whether
AVA 21.0 cm2 is an optimal criteria for AVR. To correct for this
factor, AVAI <0.6 cm2/m2 is added to the 2008 ACC/AHA practice
guidelines [6]. In the Japanese guidelines [7], however, the optimal
severity for AVR has not yet been described because no clinical
report has yet assessed the prognoses. This prospective long-term
follow-up study, therefore, has since been conducted.
Operative indication of Japanese patients 380 years old with ScAS
In the study above, patients in group A had poor prognosis,
more symptoms, and signiﬁcantly lower survival rates from all
events, including cardiac, compared to those of the other groups.
Furthermore, patients in group B have lower survival rates from
cardiac events compared to those of group M. Based on the AVAI,
group A0 has signiﬁcantly worse event-free survival rates from all
events, including cardiac, compared to groups C0 and M0. Group B0
has signiﬁcantly worse survival rates from cardiac events
H. Murakami et al. / Journal of Cardiology 65 (2015) 330–336 335compared to those of group M0. The event-free survival rates from
cardiac events based on both the AVA and AVAI show the same
outcome.
Multivariate analyses also indicate that AVA 20.6 cm2 is a
signiﬁcant risk factor for cardiac death. Kitai et al. [10]
demonstrated a signiﬁcantly worse prognosis in Japanese patients
with very severe AS (AVA <0.6 cm2), which is similar to the results
of the current study. Both studies indicate that, if possible, early
AVR or transcatheter aortic valve implantation (TAVI) should be
considered in patients with AVA 20.6 cm2. Survival from all the
endpoints in groups B, C, and M is not different while that from
only the cardiac events in group B is greater than that of group M.
Because of this ﬁnding, early AVR or TAVI for patients with
0.6 cm2 < AVA 2 0.8 cm2 should also be considered.
In the current study, multivariate data indicate that an EF 255%
is another important risk factor for cardiac events. Also in support
of the current study’s results, Shibayama et al. [4] reported that if
octogenarians with severe AS have a lowered EF <50%, early
surgery is recommended because of signiﬁcant decreases in
mortality. If AVR can be performed in patients 380 years old
with severe ScAS, both a good prognosis and a longer life can be
expected [4].
Symptoms of Japanese patients 380 years old with ScAS
62.5% of patients in group A had symptoms while only 20–30%
of the patients had symptoms in groups B and C. Similarly, Kitai
et al. [10] also showed that 66% of Japanese patients with very
severe AS (AVA <0.6 cm2) had symptoms. According to the 2008
ACC/AHA practice guidelines [6], an operative indication is
symptomatic severe AS. In fact, 48.9% of the patients with severe
ScAS in the study required partial or total assistance for ADL. They
may have restricted their activity in order to substantially avoid
symptoms. This reasoning may also result in a lower rate of
symptomatic patients; symptoms in groups B and C, therefore, are
not a reliable factor for determining AVR. Exercise testing is
recommended to detect hidden symptoms; however, almost half
of the patients 380 years old cannot physically undergo such
exercise testing. In conclusion, one criterion for determining AVR is
the symptoms due to severe AS; however, this guideline may not
be accurately assessed in elderly Japanese patients.
Factors for cardiac death in Japanese patients 380 years old with ScAS
All of the echocardiographic parameters, logistic EuroScores,
and mean arterial pressures were not different among the groups.
Cardiac function is maintained although disease severity deterio-
rates. In addition, all the echocardiographic parameters, except
AVA 20.6 cm2 and EF 255%, do not predict cardiac death. Many
other reports, however, have demonstrated that low EF, comor-
bidities (hypertension, diabetes mellitus, or ischemia), ventricular
hypertrophy, and male gender are important factors for HF or
cardiac death [11–18]. On the other hand, in patients with
preserved EF, hypertension, atrial ﬁbrillation, and female gender
are signiﬁcant risk factors [17,18]. In the current study, however,
the above risk factors have not shown any association to the
prevalence of cardiac death. Since these differences occur in the
risk factors’ association to cardiac death, further investigation is
needed.
Medications have most likely not altered the prognosis in the
current study given that several drugs, such as angiotensin-
converting enzyme inhibitors [19,20] and statins [19–21], have
been assessed as a possibility of inhibiting the deterioration of AS
and have not been found to affect it. The current study also reveals
that drugs do not affect cardiac death. Some reports, however,
demonstrate that TAVI can relieve symptoms and improve thequality of life and prognoses [22–25], similar to AVR. Since AVR and
TAVI can improve prognoses due to decreasing cardiac death, they
can be acceptable treatments for patients 380 years old with very
severe ScAS having AVA 20.8 cm2 or EF 255%.
Limitations
This study has been conducted in only a single institute, and the
number of patients is not sufﬁcient. Also, medications have not
been restricted since no effective drug has been reported for
preventing deterioration of ScAS. In addition, all of the enrolled
severe ScAS patients have a history of not desiring AVR or have
been contraindicated due to age or comorbidities; their prognosis
may be affected by both the comorbidities, especially noncardiac
deaths, and the predominant number of female patients in all the
groups.
Conclusions
Japanese patients 380 years old with ScAS having an AVA
20.6 cm2 and without AVR have a signiﬁcantly worse prognosis
and more symptoms. In severe patients 380 years old with ScAS,
therefore, an AVA 20.8 cm2 or EF 255% can be acceptable in
considering AVR or TAVI to avoid cardiac events.
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